TuisBMY • NYSE
add
Bristol-Myers Squibb Co
Vorige sluiting
$45,61
Dagwisseling
$45,43 - $46,51
Jaarwisseling
$42,52 - $63,33
Markkapitalisasie
92,95 mjd USD
Gemiddelde volume
18,65 m
P/V-verhouding
15,37
Dividend-opbrengs
5,45%
Primêre beurs
NYSE
In die nuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (USD) | Sep. 2025info | J/J-verandering |
|---|---|---|
Inkomste | 12,22 mjd | 2,77% |
Bedryfskoste | 5,05 mjd | -26,13% |
Netto inkomste | 2,20 mjd | 81,75% |
Netto winsgrens | 18,01 | 76,92% |
Wins per aandeel | 1,63 | -9,44% |
EBITDA | 4,91 mjd | 1,38% |
Effektiewe belastingkoers | 29,51% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (USD) | Sep. 2025info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 16,50 mjd | 103,88% |
Totale bates | 96,89 mjd | 3,44% |
Totale aanspreeklikheid | 78,29 mjd | 2,38% |
Totale ekwiteit | 18,60 mjd | — |
Uitstaande aandele | 2,04 mjd | — |
Prys om te bespreek | 5,01 | — |
Opbrengs op bates | 10,07% | — |
Opbrengs op kapitaal | 13,97% | — |
Kontantvloei
Netto kontantverandering
| (USD) | Sep. 2025info | J/J-verandering |
|---|---|---|
Netto inkomste | 2,20 mjd | 81,75% |
Kontant van bedrywe | 6,31 mjd | 12,88% |
Kontant van beleggings | -1,70 mjd | -677,17% |
Kontant van finansiering | -1,49 mjd | 61,32% |
Netto kontantverandering | 3,12 mjd | 95,05% |
Beskikbare kontantvloei | 4,26 mjd | -23,81% |
Meer oor
Bristol-Myers Squibb Company is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are Apixaban for people with atrial fibrillation; nivolumab, used to treat certain types of cancer; lenalidomide, used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes; abatacept, used to treat autoimmune diseases such as rheumatoid arthritis; pomalidomide, an anti-cancer medication used for the treatment of multiple myeloma and AIDS-related Kaposi sarcoma; ipilimumab, to treat cancer; and luspatercept for the treatment of anemia in beta thalassemia and myelodysplastic syndromes. In 2024, 71% of the company's revenues came from the United States.
The company is ranked 94th on the Fortune 500 and 173rd on the Forbes Global 2000.
BMS's primary research and development sites are located in Lawrence, New Jersey, Summit, New Jersey, formerly HQ of Celgene, New Brunswick, New Jersey; Redwood City, California; and Seville in Spain, with other sites in Devens and Cambridge, Massachusetts; Braine-l'Alleud, Belgium; Tokyo, Japan; Hyderabad; Bangalore, India and Wirral, United Kingdom. Wikipedia
Gestig
1887
Webwerf
Werknemers
34 100
